cdn mobile

Tech Mahindra, Med Specialized chalk up victories

By: Jonas Rey N. Panerio July 30,2019 - 08:00 AM

Tech Mahindra. | Contributed photo

Cebu City, Philippines—The Tech Mahindra Mighties garnered their second win in a row after defeating the Iploy Barracudas, 54-48, in the Evo League division of the CSCC E-Leagues For Basketball 2019 on Monday, July 29, 2019, at the City Sports Club Cebu.

Robert Rebano anchored the Tech Mighties’ offense with 11 points and four rebounds but it was Tech Mahindra’s defense that made the difference as they held their opponents to just 31 points in the last three periods to snatch the win.

In another game, the Med Specialized Unicorns bested the Demand Science Paladins, 62-52, to even their win-loss record up at 1-1.

The Unicorns rallied behind the double-double performance of Marvin Agruda, who tallied 16 points and 11 rebounds as well as two blocks. Alfie Cabriana also had a fine outing with 14 points and five boards while Ivan Yu tallied 12 points, 12 rebounds, four blocks and three assists.

And finally, the Dynata Warriors also got their first victory of the season with a 66-55 win over the Shearwater Health Crusaders. Tommy Ugsimar was magnificent against the Crusaders as he shredded the defense with 32 points, eight rebounds, six steals, two assists and two blocked shots. /bmjo

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Read Next

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

TAGS: basketball, E-Leagues, Tech Mahindra
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.